Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells

Creative Commons License

Reyes C. M., Teller S., Muckenhuber A., Konukiewitz B., Safak O., Weichert W., ...More

CLINICAL CANCER RESEARCH, vol.26, no.1, pp.220-231, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 26 Issue: 1
  • Publication Date: 2020
  • Doi Number: 10.1158/1078-0432.ccr-19-1864
  • Journal Name: CLINICAL CANCER RESEARCH
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, Agricultural & Environmental Science Database, BIOSIS, Biotechnology Research Abstracts, EMBASE, Gender Studies Database, MEDLINE
  • Page Numbers: pp.220-231
  • Acibadem Mehmet Ali Aydinlar University Affiliated: Yes

Abstract

Purpose: Neoadjuvant therapy (neoTx) has dramatically improved the prognosis of patients with locally advanced and borderline resectable pancreatic ductal adenocarcinoma, yet its mechanisms of action on tumor cells and the tumor microenvironment are still unknown. Here, we aimed to characterize the multiple facets of neoTx-induced alterations in the pancreatic cancer microenvironment.